cilostazol has been researched along with Alzheimer Disease in 21 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 5.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "In this randomized clinical trial, cilostazol was well tolerated, although it did not prevent cognitive decline." | 5.69 | Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial. ( Aso, T; Fukushima, M; Fukuyama, H; Hattori, Y; Ihara, M; Kagimura, T; Kakuta, C; Kakuta, R; Kanki, R; Kawabata, N; Kitaguchi, H; Kojima, S; Kowa, H; Maki, T; Mizuno, T; Nagatsuka, K; Nakaoku, Y; Ohtani, R; Oishi, N; Oka, N; Saito, S; Shindo, A; Shindo, K; Sudoh, S; Suzuki, K; Tachibana, H; Taguchi, A; Takahashi, R; Takahashi, Y; Taketsuna, M; Tomimoto, H; Tonomura, S; Washida, K; Yamamoto, H; Yamamoto, K; Yamamoto, Y; Yasuno, F, 2023) |
| "The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently." | 2.84 | Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction. ( Abe, K; Fukui, Y; Hishikawa, N; Ohta, Y; Sato, K; Yamashita, T, 2017) |
| " The effect is expressed through the characteristics of various pharmacokinetic processes." | 2.72 | [Pharmacokinetics/Pharmacodynamic Analysis to Link Pharmacokinetics to Efficacy and Drug Interaction of Alzheimer's Disease Drugs]. ( Kiriyama, A, 2021) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 1.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "Cilostazol is a selective PDE III inhibitor used as antiplatelet agent through cAMP response element-binding (CREB) protein phosphorylation pathway (cAMP/CREB)." | 1.72 | Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway. ( Abdelsalam, RM; Khalifa, M; Safar, MM; Zaki, HF, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Y | 1 |
| Li, Z | 1 |
| Huang, YY | 1 |
| Wu, D | 1 |
| Luo, HB | 1 |
| Cao, Z | 1 |
| Song, Q | 1 |
| Yu, G | 1 |
| Liu, Z | 1 |
| Cong, S | 1 |
| Tan, Z | 1 |
| Deng, Y | 1 |
| Xi, M | 1 |
| Sun, T | 1 |
| Chai, S | 1 |
| Xie, M | 1 |
| Chen, S | 1 |
| Deng, L | 1 |
| Du, K | 1 |
| Shen, R | 1 |
| Sun, H | 1 |
| Gomaa, AA | 1 |
| Farghaly, HSM | 1 |
| Ahmed, AM | 1 |
| El-Mokhtar, MA | 1 |
| Hemida, FK | 1 |
| Khalifa, M | 1 |
| Abdelsalam, RM | 1 |
| Safar, MM | 1 |
| Zaki, HF | 1 |
| Chien, CF | 1 |
| Huang, LC | 1 |
| Li, KY | 1 |
| Yang, YH | 2 |
| Saito, S | 4 |
| Suzuki, K | 1 |
| Ohtani, R | 1 |
| Maki, T | 1 |
| Kowa, H | 1 |
| Tachibana, H | 1 |
| Washida, K | 1 |
| Kawabata, N | 1 |
| Mizuno, T | 1 |
| Kanki, R | 1 |
| Sudoh, S | 1 |
| Kitaguchi, H | 1 |
| Shindo, K | 1 |
| Shindo, A | 1 |
| Oka, N | 1 |
| Yamamoto, K | 1 |
| Yasuno, F | 1 |
| Kakuta, C | 1 |
| Kakuta, R | 1 |
| Yamamoto, Y | 2 |
| Hattori, Y | 1 |
| Takahashi, Y | 1 |
| Nakaoku, Y | 1 |
| Tonomura, S | 1 |
| Oishi, N | 1 |
| Aso, T | 1 |
| Taguchi, A | 1 |
| Kagimura, T | 1 |
| Kojima, S | 1 |
| Taketsuna, M | 1 |
| Tomimoto, H | 1 |
| Takahashi, R | 1 |
| Fukuyama, H | 1 |
| Nagatsuka, K | 1 |
| Yamamoto, H | 1 |
| Fukushima, M | 1 |
| Ihara, M | 4 |
| Tanaka, M | 1 |
| Inoue, T | 1 |
| Satoh-Asahara, N | 1 |
| Kiriyama, A | 1 |
| Shozawa, H | 1 |
| Oguchi, T | 1 |
| Tsuji, M | 1 |
| Yano, S | 1 |
| Kiuchi, Y | 1 |
| Ono, K | 1 |
| Lee, JY | 1 |
| Lee, H | 1 |
| Yoo, HB | 1 |
| Choi, JS | 1 |
| Jung, HY | 1 |
| Yoon, EJ | 1 |
| Kim, H | 1 |
| Jung, YH | 1 |
| Lee, HY | 1 |
| Kim, YK | 1 |
| Lee, HR | 1 |
| Shin, HK | 2 |
| Park, SY | 1 |
| Kim, HY | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 2 |
| Kim, CD | 1 |
| Manousopoulou, A | 1 |
| Al-Daghri, NM | 1 |
| Carare, RO | 1 |
| Garbis, SD | 1 |
| Hishikawa, N | 1 |
| Fukui, Y | 1 |
| Sato, K | 1 |
| Ohta, Y | 1 |
| Yamashita, T | 1 |
| Abe, K | 1 |
| Nomoto, H | 1 |
| Matsubara, Y | 1 |
| Ichimiya, Y | 1 |
| Arai, H | 2 |
| Tai, SY | 1 |
| Chen, CH | 1 |
| Chien, CY | 1 |
| Takahashi, T | 1 |
| Hiramatsu, M | 1 |
| Takiguchi, O | 1 |
| Nishiyama, A | 1 |
| Mori, H | 1 |
| Park, SH | 1 |
| Kim, JH | 1 |
| Bae, SS | 1 |
| Lee, DS | 1 |
| Leem, JY | 1 |
| Choi, BT | 1 |
| Sakurai, H | 1 |
| Hanyu, H | 1 |
| Sato, T | 1 |
| Kume, K | 1 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Iwamoto, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperin[NCT01409564] | Phase 4 | 46 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The caregiver answered to the questions given to measure the cognitive function level of the patients in daily living. Lower scores indicate greater severity.~23 questions Score Scale: 0-78 (min-MAX)" (NCT01409564)
Timeframe: Baseline, 12-month, 24-month
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 12-week | 24-week | |
| Cilostazol | 50.17 | 48.00 | 46.33 |
| Placebo | 53.56 | 49.33 | 51.17 |
"The ADAS-Cog score is measured by the number of questions answered incorrectly, therefore the higher is the worse.~Score Scale: 0-75 (min-MAX)~Each subcategory scores are summed.~Word-recall test (0-10)~Commands (0-5)~Constructional praxis (0-5)~Naming Objects/ Fingers (0-5)~Ideational Praxis (0-5)~Orientation (0-8)~Word Recognition (0-12)~Remembering Test Instructions (0-5)~Spoken Language Ability (0-5)~Word Finding Difficulty (0-5)~Comprehension (0-5)" (NCT01409564)
Timeframe: Baseline, 12-week, 24-week
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 12-week | 24-week | |
| Cilostazol | 29.28 | 26.33 | 25.78 |
| Placebo | 27.78 | 24.83 | 24.78 |
"Measured by professionally trained clinicians. Higher score indicates more severe AD symptoms.~Score Scale: 0-18 (min-MAX)" (NCT01409564)
Timeframe: Baseline, 12-month, 24-month
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 12-week | 24-week | |
| Cilostazol | 5.11 | 5.42 | 5.44 |
| Placebo | 4.72 | 5.28 | 5.33 |
"Level of severity of white matter lesions in AD patients who can be legitimately administered with cilostazol. Measured by professionally trained clinicians.~The higher score indicates more severe white matter lesion. Max-min: 0-3" (NCT01409564)
Timeframe: Baseline
| Intervention | participants (Number) | ||
|---|---|---|---|
| Number of Patients Scored 1 | Number of Patients Scored 2 | Number of Patients Scored 3 | |
| Cilostazol | 13 | 3 | 2 |
| Placebo | 11 | 5 | 2 |
Basic cognitive functions are checked. (0-30) The score is better when higher. (NCT01409564)
Timeframe: Baseline, 12-month, 24-month
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 12-week | 24-week | |
| Cilostazol | 15.11 | 16.67 | 15.39 |
| Placebo | 15.44 | 15.83 | 16.22 |
Regional cerebral glucose uptake level was measured as the ratio value of FDG uptake of the each unit level to the global mean uptake value. (NCT01409564)
Timeframe: Baseline, 24-week
| Intervention | Bq/Bq (no unit) (Mean) | |||
|---|---|---|---|---|
| Left Parietal Lobe | Right Parietal Lobe | Left Inferior Frontal Gyrus | Right Inferior Frontal Gyrus | |
| Cilostazol, 24-week | 80.40 | 79.00 | 86.82 | 71.39 |
| Cilostazol, Baseline | 81.70 | 80.03 | 85.74 | 72.11 |
| Placebo, 24-week | 81.33 | 81.91 | 83.12 | 71.44 |
| Placebo, Baseline | 84.60 | 85.29 | 85.97 | 74.02 |
4 reviews available for cilostazol and Alzheimer Disease
| Article | Year |
|---|---|
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Phosphodiesterase Inhibitors | 2018 |
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiest | 2022 |
Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2020 |
[Pharmacokinetics/Pharmacodynamic Analysis to Link Pharmacokinetics to Efficacy and Drug Interaction of Alzheimer's Disease Drugs].
Topics: Acetylcholine; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cilostazol; Donepezil; Drug Co | 2021 |
6 trials available for cilostazol and Alzheimer Disease
| Article | Year |
|---|---|
Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial.
Topics: Adult; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cilostazol; Cognitive Dysfunction; Dementia; | 2023 |
Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cilostazol; Cognition | 2019 |
Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.
Topics: Aged; Alzheimer Disease; Asymptomatic Diseases; Brain; Cholinesterase Inhibitors; Cilostazol; Cognit | 2017 |
Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Case-Control Studies; Cholinesterase | 2017 |
A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cilostazol; Donepezil; Drug Therapy, Combination | 2009 |
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspirin; Cerebrovascular Circulati | 2013 |
11 other studies available for cilostazol and Alzheimer Disease
| Article | Year |
|---|---|
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; | 2021 |
Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Caffeine; Cilostazol; Diabetes Mellitus, | 2022 |
Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Animals; Cilostazol; Cyclic AMP Response | 2022 |
Cognitive effects of cilostazol in Alzheimer's dementia patients with peripheral arterial occlusive disease: A case-control study.
Topics: Acetylcholinesterase; Alzheimer Disease; Case-Control Studies; Cilostazol; Cognition; Cognitive Dysf | 2023 |
[Drug Repositioning for Alzheimer's Disease].
Topics: Alzheimer Disease; Cilostazol; Dabigatran; Drug Repositioning; Humans; Insulin; Probucol; Telmisarta | 2019 |
Supratherapeutic concentrations of cilostazol inhibits β-amyloid oligomerization in vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cilostazol; Humans; Peptide Fragments; Phosphodiesterase 3 | 2018 |
Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: targeting for cilostazol.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western | 2014 |
Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Brain; Cilostazol; Disease Models, Animal; Functional Laterality; Male; | 2016 |
Acute renal failure caused by cilostazol in a patient with Alzheimer's disease.
Topics: Acute Kidney Injury; Aged; Alzheimer Disease; Cilostazol; Humans; Male; Neuroprotective Agents; Tetr | 2017 |
Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspirin; Avoidance Learning; Cilostazol; Cytokine | 2010 |
Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cilostazol; Cognition Disorders | 2011 |